JPMorgan Chase & Co. Decreases Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

JPMorgan Chase & Co. lowered its position in MaxCyte, Inc. (NASDAQ:MXCT) by 7.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 193,999 shares of the company’s stock after selling 15,573 shares during the period. JPMorgan Chase & Co. owned approximately 0.18% of MaxCyte worth $755,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of MXCT. Mudita Advisors LLP grew its holdings in MaxCyte by 5.6% in the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock worth $12,267,000 after purchasing an additional 167,101 shares during the last quarter. Geode Capital Management LLC grew its stake in MaxCyte by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after buying an additional 47,960 shares during the last quarter. State Street Corp increased its position in MaxCyte by 5.1% during the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company’s stock valued at $8,827,000 after buying an additional 111,066 shares in the last quarter. River Global Investors LLP increased its position in MaxCyte by 4.7% during the 3rd quarter. River Global Investors LLP now owns 2,062,562 shares of the company’s stock valued at $8,034,000 after buying an additional 93,340 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its stake in MaxCyte by 13.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock valued at $5,426,000 after buying an additional 169,250 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Stock Performance

Shares of MXCT stock opened at $4.66 on Monday. MaxCyte, Inc. has a fifty-two week low of $3.16 and a fifty-two week high of $5.29. The firm has a market capitalization of $492.61 million, a price-to-earnings ratio of -13.71 and a beta of 1.29. The stock’s 50-day simple moving average is $4.15 and its 200-day simple moving average is $4.08.

MaxCyte (NASDAQ:MXCT) last released its earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same quarter in the previous year, the firm earned ($0.11) EPS. As a group, equities analysts forecast that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.